FINWIRES · TerminalLIVE
FINWIRES

达能确认2026年业绩展望,但配方奶粉召回事件和中东战争影响季度销售额

-- 尽管受欧洲婴儿配方奶粉召事件和中东冲突的影响,达能(BN.PA)周三维持了其2026年的业绩预期,但第一季度报告的销售额同比下降了2%。 这家法国食品公司截至3月31日的三个月内,销售额从去年同期的68.4亿欧元降至67.1亿欧元,原因是市场扩张和恶性通货膨胀带来的积极影响被外汇逆风所抵消。FactSet调查的分析师此前预期销售额为66.9亿欧元。 然而,按可比口径计算,由于销量/产品组合增长1.5%以及价格上涨1.2%,销售额增长了2.7%。达能表示,尽管市场环境充满挑战,但其在欧洲、中东和非洲的业绩依然“稳健”,同店销售额增长了0.6%。 美洲地区的增长提升了3.4%,这主要得益于美国市场在拉丁美洲持续强劲表现的推动下重拾增长势头。亚太地区同店销售额增长了6%,这主要得益于中国市场对特殊营养品的需求以及日本市场对基础乳制品和植物基产品(EDP)的需求。按品类划分,EDP销售额增长了3.4%,特殊营养品和饮用水的销售额分别增长了1.9%和2.3%。 首席执行官安托万·德·圣阿弗里克表示:“我们领先的产品平台继续保持强劲表现,尤其是在高蛋白乳制品、冰岛酸奶和开菲尔酸奶,依云和美舒诺饮用水,以及全球范围内的医用营养品领域。我们对以科学为基础、以消费者和患者为中心的策略充满信心,并重申全年业绩预期。” 为实现中期目标,公司重申了其2026年同店销售额年增长率3%至5%的预期,并预计经常性营业收入的增长速度将超过销售额的增长速度。 加拿大皇家银行资本市场表示:“有机销售增长2.7%,与市场预期相符,但低于全年3-5%的预期。受欧洲国际货币基金组织(IMF)召回事件的影响,专业营养品业务的业绩比预期低75个基点,但得益于EDP的良好表现,欧洲、中东和非洲地区(EMEA)整体业绩超出预期。我们相信达能能够加速品类增长,并持续实现3-5%的有机销售增长预期。” 周三中午,达能股价在巴黎上涨3%。

Related Articles

Asia

Easou Technology Invests $7.7 Million in Wealth Product Using Idle Top-up Placing Funds

Easou Technology (HKG:2550) said it has subscribed to a $7.7 million wealth management product issued by Huatai International Financial Products, using idle proceeds from its earlier placings, according to a Friday Hong Kong bourse filing.Shares of the digital service firm were down over 1% in Monday's late-morning trade.The investment, guaranteed by Huatai International Financial, carries an annualized return of 1.07% to 5.83% over a term ending March 30, 2027.Easou said the move aims to enhance the utilization efficiency and returns on idle funds while maintaining liquidity.

$HKG:2550
Asia

SSY Group Gets Chinese Regulatory Nod for Production, Registration of Two Products

SSY Group (HKG:2005) said it received Chinese regulatory approval to begin drug production and registration of its diltiazem hydrochloride in injection form, according to a Hong Kong bourse filing Monday.The drug is mainly used to treat a heart condition known as supraventricular tachycardia and the emergency treatment of abnormally high blood pressure during surgery.The firm's propranolol hydrochloride injection was also approved for production and registration by China's National Medical Products Administration.The product is mainly used to treat supraventricular tachyarrhythmias and ventricular arrhythmias.

$HKG:2005
Asia

Amplitude Energy Says Australian Retirement Trust Raises Stake

Amplitude Energy (ASX:AEL) said Australian Retirement Trust raised its stake in the firm to 6.3% as of Friday from 5.1% as of April 2, according to a Monday Australian bourse filing.Australian Retirement Trust now holds nearly 19 million votes in the firm.

$ASX:AEL